contact us
subTop TechOffers
  • Patients suffering from AMD and DR often require anti-vascular endothelial growth factor (anti-VEGF) agent injections into the eye
  • Multiple injections are uncomfortable and difficult for patients to comply to
  • Ocular and systemic safety of repeated injections unclear

 

Market Impact
  • More than 10,000 injections per year are performed at the Singapore National Eye Centre (SNEC)
  • 66 million people are affected by AMD, increasing at a rate of 1.85% annually from 2013
  • Treatment market across US, UK, Germany, France, Spain, Italy and Japan will almost double in value from $5.1 billion in 2013 to $10.1 billion by 2023.

 

Technology Description
  • SERID simultaneously injects therapeutic agents into the eye and extracts vitreous samples for biomarker analysis in a single puncture
  • The device comprises an injection port, a vacuum port, and at least one needle for selective fluid communication between the injection and vacuum port.
  • The device removes vitrous sample first to minimize a spike in the intraocular pressure, then the drug is administered in the same injection.
  • The injection mechanism is currently an adapted 1mL syringe

 

Development Status
  • Preliminary ex vivo studies with porcine eyes has shown the mechanism and advantages of SERID.

Current IP Position: National Phase under examination (PCT/SG2016/050119 filed on 15 March 2016)

 

Future Progress

Seeking further funding opportunities into the start-up and/or collaboration to further enhance the existing system.

 

Dr Marcus Ang / SingHealth

 

targetGroup_clinicianInnovators
targetGroup_ResearchAdministrator
targetGroup_IndustryPartner
targetGroup_Investor